{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:02:42Z","timestamp":1793041362031,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Nantong Citizen Life Science and Technology Project","award":["MS12020031"],"award-info":[{"award-number":["MS12020031"]}]},{"name":"Postgraduate Research & Practice Innovation Program of Jiangsu Province","award":["KYCX21_3115"],"award-info":[{"award-number":["KYCX21_3115"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Retinal vein occlusion (RVO) is the main cause of retinal vascular blindness. Laser photocoagulation therapy is the regarded as the standard treatment for branch retinal vein occlusion (BRVO) in the guidelines, but it is not effective for macular edema (ME) secondary to central retinal vein occlusion (CRVO). As anti-VEGF (vascular endothelial growth factor) or steroids monotherapy has been used to treat RVO, but each has its advantages and disadvantages. Our purpose was to evaluate the efficacy and safety of intraocular injection of anti-VEGF combined with steroids versus anti-VEGF or steroids monotherapy for ME secondary to RVO.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We systematically searched trials on Pubmed, Embase, Cochrane Library, Web of Science and China National Knowledge Infrastructure (CNKI) for RCTs (random clinical trials) or non-RCTs, comparing anti-VEGF or steroids monotherapy to their combination. The primary outcomes were changes in best-corrected visual acuity (BCVA), central macular thickness (CMT) and intraocular pressure (IOP). The pooled data was analyzed by random effects model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Findings<\/jats:title>\n                <jats:p>A total of 10 studies selected from 366 studies were included in this meta-analysis. Our results favored anti-VEGF with steroids combination therapy in comparison with anti-VEGF {pooled SMD (standardized mean difference), 95% CI, -0.16 [-0.28, -0.04], <jats:italic>P<\/jats:italic>\u2009=\u20090.01} or steroids (pooled SMD, 95% CI, -0.56 [-0.73, -0.40], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001) alone on changes of BCVA. Compared with anti-VEGF monotherapy group, the combination therapy also had a better effect {pooled MD (mean difference), 95% CI, -9.62 [-17.31, -1.93], <jats:italic>P<\/jats:italic>\u2009=\u20090.01)} at improvements on CMT. On the changes of IOP, assessment favored that combination therapy was associated with a better relief of IOP compared to steroids monotherapy group (pooled MD, 95% CI, -5.93 [-7.87, -3.99],<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.00001). What\u2019s more, the incidence of ocular hypertension was lower in the combined treatment group compared with control group treated with steroids alone (Odds Ratio, 95% CI, 0.21 [0.06, 0.77], <jats:italic>P<\/jats:italic>\u2009=\u20090.02). Results also showed that the combination group can prolong the average time to first anti-VEGF reinjection (MD, 95% CI, 1.74 [0.57, 2.90], <jats:italic>P<\/jats:italic>\u2009=\u20090.003) compared to control group treated with anti-VEGF alone.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Anti-VEGF with steroids combination treatment can enable a better achievement of improving BCVA, CMT, reducing the risk of increased IOP and improving patient prognosis compared to anti-VEGF or steroids therapy alone, lengthening the average time to anti-VEGF reinjection with reducing the injections during follow-up.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02682-7","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:06:47Z","timestamp":1670335607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and effectiveness of anti-VEGF or steroids monotherapy versus combination treatment for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Wuyue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"issue":"1","key":"2682_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.22608\/APO.2017442","volume":"7","author":"M Ip","year":"2018","unstructured":"Ip M, Hendrick A. Retinal vein occlusion review. Asia Pac J Ophthalmol (Phila). 2018;7(1):40\u20135. https:\/\/doi.org\/10.22608\/APO.2017442.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"6","key":"2682_CR2","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.3390\/nu5061962","volume":"5","author":"E Loskutova","year":"2013","unstructured":"Loskutova E, Nolan J, Howard A, Beattyet S. Macular pigment and its contribution to vision. Nutrients. 2013;5(6):1962\u20139. https:\/\/doi.org\/10.3390\/nu5061962.","journal-title":"Nutrients."},{"issue":"10","key":"2682_CR3","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/s0161-6420(95)30849-4","volume":"102","author":"JG Clarkson","year":"1995","unstructured":"Clarkson JG, Chuang E, Gass D, Pedroso M, Cubillas T, Duria ES. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology. 1995;102(10):1425\u201333. https:\/\/doi.org\/10.1016\/s0161-6420(95)30849-4.","journal-title":"Ophthalmology"},{"issue":"2","key":"2682_CR4","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1167\/iovs.14-15789","volume":"56","author":"H Noma","year":"2015","unstructured":"Noma H, Mimura T, Yasuda K, Yasuda K, Shimura M. Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema. Invest Ophthalmol Vis Sci. 2015;56(2):1122\u20138. https:\/\/doi.org\/10.1167\/iovs.14-15789.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"2682_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000502041","volume":"242","author":"U Schmidt-Erfurth","year":"2019","unstructured":"Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, Midena E, Sivaprasad S, Tadayoni R, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242(3):123\u201362. https:\/\/doi.org\/10.1159\/000502041.","journal-title":"Ophthalmologica"},{"key":"2682_CR6","doi-asserted-by":"publisher","first-page":"432685","DOI":"10.1155\/2014\/432685","volume":"2014","author":"FJ Ascaso","year":"2014","unstructured":"Ascaso FJ, Huerva V, Grzybowski A. The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases. Mediators Inflamm. 2014;2014:432685. https:\/\/doi.org\/10.1155\/2014\/432685.","journal-title":"Mediators Inflamm"},{"issue":"12","key":"2682_CR7","doi-asserted-by":"publisher","first-page":"e0144894","DOI":"10.1371\/journal.pone.0144894","volume":"10","author":"Y Muraoka","year":"2015","unstructured":"Muraoka Y, Tsujikawa A, Takahashi A, Iida Y, Murakami T, Ooto S, et al. Foveal damage due to subfoveal hemorrhage associated with branch retinal vein occlusion. PLoS ONE. 2015;10(12):e0144894. https:\/\/doi.org\/10.1371\/journal.pone.0144894.","journal-title":"PLoS ONE"},{"issue":"1","key":"2682_CR8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.18008\/1816-5095-2019-1-95-101","volume":"16","author":"MV Budzinskaya","year":"2019","unstructured":"Budzinskaya MV, Shelankova AV, Plukhova AA. The role of steroids in the management of macular edema from retinal vein occlusion. Oftalmologia. 2019;16(1):95\u2013101. https:\/\/doi.org\/10.18008\/1816-5095-2019-1-95-101.","journal-title":"Oftalmologia"},{"issue":"9","key":"2682_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ajo.2016.04.020","volume":"169","author":"H Hoerauf","year":"2016","unstructured":"Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, et al. Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. Am J Ophthalmol. 2016;169(9):258\u201367. https:\/\/doi.org\/10.1016\/j.ajo.2016.04.020.","journal-title":"Am J Ophthalmol."},{"issue":"4","key":"2682_CR10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00417-019-04577-8","volume":"258","author":"C Giuffre","year":"2020","unstructured":"Giuffre C, Cicinelli MV, Marchese A, Coppola M, Parodi MB, Bandello F. Simultaneous intravitreal dexamethasone and aflibercept for refractory macular edema secondary to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2020;258(4):787\u201393. https:\/\/doi.org\/10.1007\/s00417-019-04577-8.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"2682_CR11","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors) development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg"},{"issue":"10","key":"2682_CR12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3109\/02713683.2010.496540","volume":"35","author":"O Cekic","year":"2010","unstructured":"Cekic O, \u00c7ak\u0131r M, Yaz\u0131c\u0131 AT, Alag\u00f6z N, Bozkurt E, Y\u0131lmaz OF. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Curr Eye Res. 2010;35(10):925\u20139. https:\/\/doi.org\/10.3109\/02713683.2010.496540.","journal-title":"Curr Eye Res"},{"key":"2682_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ajo.2017.11.020","volume":"186","author":"AS Willoughby","year":"2018","unstructured":"Willoughby AS, Vuong VS, Cunefare D, Farsiuet S, Noronha G, Danis RP, et al. Choroidal changes after suprachoroidal injection of triamcinolone acetonide in eyes with macular edema secondary to retinal vein occlusion. Am J Ophthalmol. 2018;186:144\u201351. https:\/\/doi.org\/10.1016\/j.ajo.2017.11.020.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"2682_CR14","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/eye.2016.96","volume":"30","author":"J Moon","year":"2016","unstructured":"Moon J, Kim M, Sagong M. Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion. Eye (Lond). 2016;30(8):1084\u201390. https:\/\/doi.org\/10.1038\/eye.2016.96.","journal-title":"Eye (Lond)"},{"issue":"9","key":"2682_CR15","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3109\/02713683.2014.885533","volume":"39","author":"C Fan","year":"2014","unstructured":"Fan C, Wang Y, Ji Q, Zhao B, Xie J. Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion. Curr Eye Res. 2014;39(9):938\u201343. https:\/\/doi.org\/10.3109\/02713683.2014.885533.","journal-title":"Curr Eye Res"},{"issue":"4","key":"2682_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.oret.2017.07.013","volume":"2","author":"PA Campochiaro","year":"2018","unstructured":"Campochiaro PA, Wykoff CC, Brown DM, Boyer DS, Barakat M, Taraborelli D, et al. Suprachoroidal triamcinolone acetonide for retinal vein occlusion: results of the tanzanite study. Ophthalmol Retina. 2018;2(4):320\u20138. https:\/\/doi.org\/10.1016\/j.oret.2017.07.013.","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"2682_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3341\/kjo.2014.28.1.19","volume":"28","author":"K Lee","year":"2014","unstructured":"Lee K, Jung H, Sohn J. Comparison of injection of intravitreal drugs with standard care in macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol. 2014;28(1):19\u201325. https:\/\/doi.org\/10.3341\/kjo.2014.28.1.19.","journal-title":"Korean J Ophthalmol"},{"key":"2682_CR18","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2147\/OPTH.S60159","volume":"8","author":"RK Maturi","year":"2014","unstructured":"Maturi RK, Maturi RK, Chen V, Raghinaru D, Bleau L, Stewart MW. A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion. Clin Ophthalmol. 2014;8:1057\u201364. https:\/\/doi.org\/10.2147\/OPTH.S60159.","journal-title":"Clin Ophthalmol"},{"key":"2682_CR19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3760\/cma.j.cnl16022-20211010-00357","volume":"03","author":"T Zheng","year":"2022","unstructured":"Zheng T, Zhang JS, Liu D. Efficacy of aflibercept combined with triamcinolone acetonide for the treatment of macular edema secondary to central retinal vein occlusion. Chin J Ocul Traum Occupat Eve Dis. 2022;03:230\u20135. https:\/\/doi.org\/10.3760\/cma.j.cnl16022-20211010-00357.","journal-title":"Chin J Ocul Traum Occupat Eve Dis"},{"key":"2682_CR20","first-page":"122","volume":"03","author":"XZ Zhao","year":"2018","unstructured":"Zhao XZ, He B. The curative effect of conbercept combined with triamcinolone acetonide in the treatment of macular edema secondary to central retinal vein occlusion. J Clin Med. 2018;03:122\u20134.","journal-title":"J Clin Med"},{"key":"2682_CR21","first-page":"127","volume":"03","author":"YP Duan","year":"2019","unstructured":"Duan YP, Hu Y, Liu Y, Ren Y. The curative effect of intravitreal injection of Conbercept combined with triamcinolone ace- tonide in the treatment of macular edema secondary to retinal vein occlusion. J Clin Med. 2019;03:127\u201330.","journal-title":"J Clin Med"},{"issue":"6","key":"2682_CR22","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3390\/life11060572","volume":"11","author":"Y Sakanishi","year":"2021","unstructured":"Sakanishi Y, Morita S, Mashimo K, Tamaki K, Ebihara N. Subfoveal choroidal thickness and treatment outcomes of intravitreal aflibercept for branch retinal vein occlusion. Life (Basel). 2021;11(6):572. https:\/\/doi.org\/10.3390\/life11060572.","journal-title":"Life (Basel)"},{"issue":"2","key":"2682_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000437276","volume":"234","author":"KH Kim","year":"2015","unstructured":"Kim KH, Lee DH, Lee JJ, Park SW, Byon IS, Lee EJ. Regional choroidal thickness changes in branch retinal vein occlusion with macular edema. Ophthalmologica. 2015;234(2):109\u201318. https:\/\/doi.org\/10.1159\/000437276.","journal-title":"Ophthalmologica"},{"issue":"2","key":"2682_CR24","first-page":"436","volume":"38","author":"RM Kurtz","year":"1997","unstructured":"Kurtz RM, Elner VM, Bian ZM, Strieter RM, Kunkel SL, Elner SG. Dexamethasone and cyclosporin a modulation of human retinal pigment epithelial cell monocyte chemotactic protein-1 and interleukin-8. Invest Ophthalmol Vis Sci. 1997;38(2):436\u201345.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"2682_CR25","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1167\/iovs.06-1041","volume":"48","author":"S Mizuno","year":"2007","unstructured":"Mizuno S, Nishiwaki A, Morita H, Miyake T, Ogura Y. Effects of periocular administration of triamcinolone acetonide on leukocyte-endothelium interactions in the ischemic retina. Invest Ophthalmol Vis Sci. 2007;48(6):2831\u20136. https:\/\/doi.org\/10.1167\/iovs.06-1041.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"2682_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1159\/000451062","volume":"236","author":"H Noma","year":"2016","unstructured":"Noma H, Mimura T, Yasuda K, Nakagawa H, Motohashi R, Kotake O, Shimura M. Cytokines and recurrence of macular edema after intravitreal ranibizumab in patients with branch retinal vein occlusion. Ophthalmologica. 2016;236(4):228\u201334. https:\/\/doi.org\/10.1159\/000451062.","journal-title":"Ophthalmologica"},{"issue":"6","key":"2682_CR27","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41433-019-0616-7","volume":"34","author":"A Sharma","year":"2020","unstructured":"Sharma A, Kuppermann BD, Bandello F, Lanzetta P, Zur D, Park SW, Yu HG, et al. Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations-GEODEX-IOP study. Eye (Lond). 2020;34(6):1063\u20138. https:\/\/doi.org\/10.1038\/s41433-019-0616-7.","journal-title":"Eye (Lond)"},{"issue":"4","key":"2682_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jcjo.2020.01.015","volume":"55","author":"PP Storey","year":"2020","unstructured":"Storey PP, Patel D, Garg S. Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents. Can J Ophthalmol. 2020;55(4):286\u201392. https:\/\/doi.org\/10.1016\/j.jcjo.2020.01.015.","journal-title":"Can J Ophthalmol"},{"issue":"6","key":"2682_CR29","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/s0002-9394(14)74791-9","volume":"113","author":"RM Feist","year":"1992","unstructured":"Feist RM, Ticho BH, Shapiro MJ, Farber M. Branch retinal vein occlusion and quadratic variation in arteriovenous crossings. Am J Ophthalmol. 1992;113(6):664\u20138. https:\/\/doi.org\/10.1016\/s0002-9394(14)74791-9.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"2682_CR30","doi-asserted-by":"publisher","first-page":"14103","DOI":"10.1038\/s41598-022-18414-2","volume":"12","author":"YJ Choi","year":"2022","unstructured":"Choi YJ, Jee D, Kwon JW. Characteristics of major and macular branch retinal vein occlusion. Sci Rep. 2022;12(1):14103. https:\/\/doi.org\/10.1038\/s41598-022-18414-2.","journal-title":"Sci Rep"},{"issue":"1","key":"2682_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/IAE.0000000000000256","volume":"35","author":"SS Hayreh","year":"2015","unstructured":"Hayreh SS, Zimmerman MB. Fundus changes in central retinal vein occlusion. Retina. 2015;35(1):29\u201342. https:\/\/doi.org\/10.1097\/IAE.0000000000000256.","journal-title":"Retina"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02682-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02682-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02682-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T14:08:50Z","timestamp":1670335730000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02682-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2682"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02682-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"6 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declared that they had no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"472"}}